MedTrace Logo

Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

NCT01199302 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2021-12-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.

Conditions

Interventions

BIOLOGICAL

Brodalumab

Administered intravenously once every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-02
Primary Completion
2011-10-18
Completion
2011-10-18

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • France
  • Netherlands
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199302 on ClinicalTrials.gov